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METHODOLOGY Open Access
Optimising recruitment into trials using an
internal pilot
W. Bertram1,2* , A. Moore1, V. Wylde1,3 and R. Gooberman-Hill1,3
Abstract
Background: Recruitment to trials can be difficult. Despite careful planning and research that outlines ways to
improve recruitment, many trials do not achieve their target on time and require extensions of funding or time.
Methods: We describe a trial in which an internal pilot with embedded qualitative research was used to improve
recruitment processes and inform recruitment projections for the main trial. At the end of the pilot, it was clear that
the sample size would not be met on time. Three steps were taken to optimise recruitment: (1) adjustments were
made to the recruitment process using information from the qualitative work done in the pilot and advice from a
patient and public involvement group, (2) additional recruiting sites were included based on site feasibility assessments
and (3) a projection equation was used to estimate recruitment at each site and overall trial recruitment.
Results: Qualitative work during the pilot phase allowed us to develop strategies to optimise recruitment during the
main trial, which were incorporated into patient information packs, the standard operating procedures and training
sessions with recruiters. From our experience of feasibility assessments, we developed a checklist of recommended
considerations for feasibility assessments. For recruitment projections, we developed a four-stage projection equation
that estimates the number of participants recruited using a conversion rate of the number randomised divided by the
number screened.
Conclusions: This work provides recommendations for feasibility assessments and an easy-to-use projection tool,
which can be applied to other trials to help ensure they reach the required sample size.
Trial registration: ISRCTN, ISRCTN92545361. Registered on 6 September 2016.
Background
When designing trials, good estimates of recruitment
targets are needed. This enables study timeframes and
budgets to be properly calculated and enables practical-
ities, such as the number of study centres, to be planned
for. Despite careful planning, many trials struggle to
achieve their recruitment targets within the expected
timeframe. In a survey of UK clinical trial units, this was
found to be the most commonly listed inefficiency in
trials [1]. Numerous trials have stopped because they
have not been able to recruit sufficient participants or
have finished with fewer participants than planned [2].
Extensions of time and funding are required in around
half of publicly funded trials [3–5]. In recent years, re-
search has addressed trial recruitment, which has led to
recommendations of strategies that may influence or
improve recruitment, such as telephone reminders,
financial and non-monetary incentives, envelopes with
handwritten addresses, addressing external influences,
using a patient-centred approach, making interventions
available only in the trial and a dedicated trial manager
[3, 6–10]. Despite this, questions remain unanswered
about how to improve recruitment [11, 12].
Many authors have published on the difficulties in
recruiting patients to trials and achieving complete samples
[13]. Recruitment targets are often overly optimistic.
Lasagna’s law—developed based on a trial in which only
100 patients were recruited from a potentially eligible
population of over 8000 [14]—states that investigators
overestimate the number of patients who may be available
for a trial. The same phenomenon is described in Meunch’s
third law, which states that any recruitment estimate
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should be divided by ten [15]. Despite much work that
explores how to enhance recruitment, Lasagna’s law still
holds true [16]. Less attention has been paid to how to
estimate realistic recruitment rates in the first instance.
Pilot phases (either internal or external) in trials are of
particular value to the estimation of recruitment rates
and strategies and are part of good trial design and
practice [17, 18]. Internal pilots are useful for bringing
unexpected practicalities to light that may be seen only
once a trial is in the delivery phase.
Because of recruitment challenges, trial teams often
need to expand to more centres or seek a time or funding
extension to facilitate recruitment to target, while others
do not recruit enough patients to answer their question.
This is an inefficient use of resources, including time,
money and effort for patients, researchers and funders
[19, 20]. The key to achieving recruitment targets is to set
them realistically by conducting a thorough feasibility
assessment and using the information from this to create
projections. This can be done using information from an
internal pilot study. This article presents a case study of a
randomised controlled trial in which we used information
from an internal pilot phase to improve recruitment
processes, undertake site feasibility assessments and create
a projection tool to inform implementation of changes to
the trial processes. Methods for predicting recruitment
can be done using statistical packages [21, 22], but many
researchers and trial managers do not have the training,
time or resources to utilise them.
Our aim is to provide an overview of implementable
methods of optimising recruitment, which research teams
can use to increase the likelihood that recruitment targets
are met.
Case study: the STAR trial
This example describes the STAR trial, a randomised
controlled trial that evaluated the clinical effectiveness
and cost-effectiveness of a new care pathway for patients
with chronic pain after a knee replacement. The trial
was planned to run at four sites with a target sample size
of 380. The full protocol has been published [23].
Recruitment was projected equally between centres with
an estimated recruitment rate of 3 patients per month
for all four sites combined during a 6-month pilot and
15 patients per month thereafter for a total of 30months.
Chronic pain after a knee replacement affects about 20%
of patients, and therefore around 1 in 5 patients under-
going a total knee replacement would be eligible for the
STAR trial [24–26]. Screening processes for the trial were
piloted before the trial started and demonstrated a con-
version rate of 7.6%, which is around 7–8 randomised
patients per 100 screened [27]. The trial screening and
recruitment processes are outlined in the flow chart in
Additional file 1.
Result
Internal pilot
Internal pilots can help to identify unexpected recruit-
ment issues. A 6-month internal pilot was run within
the trial to refine recruitment procedures. This was
undertaken following work with the same patient popu-
lation to refine the intervention [27]; therefore, we did
not conduct a separate feasibility study. At the comple-
tion of the pilot, the recruitment data were used to
develop projections. These showed a predicted total of
166 randomisations at the end of the 30-month recruit-
ment period. It was clear that the sample size of 380
would not be met on time. Three steps were undertaken
to optimise recruitment following the pilot:
1. Adjustments were made to the recruitment process
using information from qualitative work done in the
pilot and advice from a patient and public
involvement group.
2. Additional recruiting sites were included based on
site feasibility assessments.
3. A projection equation was used to estimate
recruitment at each site and overall trial
recruitment.
Step 1: embedded qualitative research
Recent research has demonstrated the benefit of
using qualitative methods to inform refinements to
trial processes and to optimise recruitment and re-
tention rates [28, 29]. As part of the work within the
pilot, we employed qualitative methods to identify
and understand the motivations and possible barriers
to participation of our target patient population. We
used a dynamic approach commensurate with the
trial design and the aims of the qualitative work [30],
which were to identify barriers to recruitment and
retention, and to optimise the accessibility of trial in-
formation and informed consent. Our approach in-
volved audio-recording recruitment consultations
between patients and recruiters, and follow-up tele-
phone interviews with participants after they had
been randomised.
Using purposive sampling [31] to ensure that data
were elicited from patients and recruiters from a
variety of trial sites, we aimed to record 30 recruit-
ment consultations and conduct telephone follow-up
interviews with 30 participants to explore their
experience of trial recruitment and to identify facili-
tators and barriers to recruitment and retention, and
the accessibility of trial information. The sample size
was calculated as most likely to achieve data satur-
ation [32]. During the recruitment consultation,
patients were invited to participate in a follow-up
telephone interview about their experiences of the
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recruitment process and randomisation. These
interviews were conducted by an experienced
qualitative researcher not previously known to the
participants (AM) and audio-recorded with the par-
ticipants’ written consent. Altogether, 31 recruitment
consultations were audio-recorded, lasting a mean of
25 min, and 29 telephone interviews conducted, last-
ing a mean average of 17 min. Transcripts were
coded and analysed using a thematic approach [33].
All our interpretations are based on an analysis of
the transcribed data. Findings relevant to patient un-
derstanding of trial processes and information,
illustrative data and actions are provided in Add-
itional file 2. In summary:
 Some patients thought that the randomisation result
reflected a calculated ‘need’ for the intervention
based on their responses to the questionnaire.
Further analysis showed that recruiters explained
the use of questionnaires and entry of responses into
a database just prior to explaining randomisation, so
the link appeared natural.
 During the recruitment consultations, one patient
was unsure about the term ‘ongoing treatment’ in
reference to a statement in the patient information
leaflet (PIL) that patients’ ongoing treatment would
not be affected.
 One participant thought that they would be
attending the clinic on multiple occasions as part of
a group, which concerned them because of work
commitments.
 Some participants experienced problems when
selecting answers to questions in the online version
of the outcome questionnaire.
Based on this information, the project team made
the following changes to the recruitment process,
PIL and questionnaires. We set up a working group
to develop an improved explanation in the PIL of
randomisation and the need for fair comparisons in
trials. Moreover, we updated the standard operating
procedures for recruiters to ensure that they made a
clear distinction between completion of the ques-
tionnaire and the randomisation procedure. We ex-
panded the description of usual care provided in the
PIL to ensure that patients understood that all par-
ticipants, regardless of group allocation, would still
be able to access medical care as usual. We clarified
in the PIL that patients would attend only one
clinic appointment. Finally, the online version of the
questionnaire was modified to ensure that partici-
pants could select options more easily.
During training sessions with recruiters, findings from
the qualitative work were presented and discussed,
ensuring that recruiters felt confident and supported
during the main trial phase, and regular contact was
maintained thereafter. Regular reports from the qualita-
tive findings were also presented at trial management
group meetings, steering committee meetings and pa-
tient and public involvement meetings, for discussion
and reflection. The qualitative work helped us to develop
strategies to optimise recruitment during the main trial.
Patient and public involvement
We collaborated with a study-specific patient and public
involvement group to seek advice on patient documents
and how to improve recruitment and retention methods
[34]. The group met on five occasions before the trial
and offered advice on the content and format of the
plain English summary, PILs, questionnaires, resource-
use diaries and interview topic guides. The group met
three times during the pilot to review trial progress and
give advice on standard operating procedures. Advice
given included that research staff making phone calls or
home visits should give patients plenty of time to answer
the telephone or door as a painful knee can make getting
up to walk difficult, especially after sitting for a long time.
At the end of the pilot, we reviewed the findings with the
group, who made recommendations about patient in-
volvement in researcher training and updates to recruit-
ment standard operating procedures, including how to
explain usual care. The group met regularly throughout
the trial and will give advice on how to communicate find-
ings to patients and the public.
Step 2: site feasibility assessments
A feasibility assessment is an evaluation of whether there
is capacity and capability for a trial to be carried out at a
site or group of sites. This trial management process is
distinctly different from a feasibility study [30]. It is
widely used in commercial research when selecting par-
ticipating sites for clinical trials and in National Health
Service (NHS) research departments in the United
Kingdom when deciding whether there is capacity and
capability to undertake delivery of a trial as a recruiting
site. The process may help to identify barriers to recruit-
ment and establish realistic recruitment targets and
timelines [35]. An overview of the process and its im-
portance is covered in the National Institute for Health
Research (NIHR) good clinical practice training, which
focuses on four considerations: patient population, study
team, clinical support services, and equipment and faci-
lities [36]. It is also important to consider external
factors that may influence recruitment, such as changes
in clinical guidelines or practices [8]. Assessing feasibility
after a trial has opened can be useful in identifying
issues with recruitment and informing the selection of
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additional sites. The key aspects of our feasibility assess-
ments are described below.
Here is a summary of the recommended considerations
for feasibility assessments:
– Patient population
 Gain accurate estimates of how many patients are
available.
 Consider patient burden when estimating
recruitment rates.
 Consult a patient and public involvement group.
 Embed qualitative research within the internal pilot.
 Consider regional differences in patient
populations.
– Study sites
 Use multiple methods to identify sites, e.g.
registries, local research departments and
networks.
 Send an expression of interest form to potential
sites to collect feasibility information.
 Expression of interest forms should ask for the
following information:
○ The trial team: training and experience,
protected time available, cover arrangements
○ A description of the current standard
practice or treatment
○ How the current standard differs from or
conflicts with the trial intervention
○ The number of potentially eligible patents
and how this number was calculated
○Whether all (or some) clinicians support the
recruitment of their patients
○Why some clinicians may not want to be
involved
○ Any conflicting trials currently running or
being set up
○ The number of trials the principal
investigator is currently overseeing
○Whether support is available for additional
costs
– Training, equipment and materials
 Consider how much training is required for staff,
and whether this will be provided centrally or on
site.
 Plan well in advance to account for busy
schedules.
 Specify if any specialist equipment or testing is
needed, and clarify how or if the site can
accommodate this.
– Setup
 Approval processes will differ between sites: be
prepared for delays and ask for timelines.
 Ask each site what they need to move forward
and stay in regular contact.
Patient population
First, we estimated the patient population at each potential
trial site by searching local hospital systems, requesting data
from hospital informatics departments and consulting data
published by the UK National Joint Registry. Where elec-
tronic information was not available, we manually counted
entries from clinic or procedure lists. Next, we estimated
the number of patients who may want to take part in the
trial. Regional variations in recruitment between each site
were discussed with local research teams, who gave advice
based on their previous experiences with the same or simi-
lar patient populations. Populations at recruiting sites were
assessed using regular screening log submissions.
Site selection
Information published by the UK National Joint Registry
identified hospitals performing a high volume of total knee
replacements. Local research and development departments
and research networks were consulted to help identify con-
tacts who could be sent expression of interest requests.
These requests were sent to many potential centres with a
brief (one page) summary of the trial, either directly or via
an intermediate contact, such as a local research network.
The information required to conduct a feasibility assessment
for a new site was requested in the expression of interest
questionnaire, which can be found in Additional file 3. A
deadline was placed on the return of the questionnaire.
The expression of interest asked for the number of
eligible patients and how this figure was obtained, for ex-
ample from hospital informatics departments. At one
high-volume potential site, only half the clinicians agreed
to allow the participation of patients they had treated.
Thus, since not all the clinicians on some sites may be
willing for the patients under their care to be recruited,
we adjusted the targets and projections. An additional site
was required to make up for the lost screening population.
We considered each clinician’s reasons for not including
patients, as these may be the same at other sites. We also
investigated whether other studies were being run involv-
ing the same patient population, so that we had a sense of
whether there was a risk that patients might be overbur-
dened or invited to take part in other studies that might
preclude their involvement in the trial, or vice versa.
This trial involved excess treatment costs. We found
it was important to be transparent to sites about
these costs as well as about payments.
Step 3: projections
After the pilot, we found that it was important not simply
to divide the required sample size by the number of partici-
pating sites and assume each site would recruit equally.
Some sites had differing numbers of available patients and
recruitment targets were, therefore, weighted accordingly.
Setup times were also considered, including a time lag
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between the commencement of screening and enrolment
of the first participant. We used projections to estimate the
monthly and overall recruitment from each site and ad-
justed these as the trial progressed to account for higher or
lower recruitment. Our model used the estimated total
number of participants to predict recruitment using a con-
version rate of the number randomised divided by the
number screened. The four-stage process is outlined below.
Stage 1: quantify the patient population
The Stage 1 metric is the total number of available poten-
tial participants to be screened in a given amount of
time. We first clarified the different circumstances for each
site. It was important to understand how their current clin-
ical practice differs from the research intervention and how
this might affect patient recruitment. Reliable information
about the patient population was sourced from the National
Joint Registry or electronic hospital databases to avoid using
unrealistic estimates. Screening logs were submitted
monthly by each recruiting site and were used to clarify the
patient population. Stage one in the equation below repre-
sents the total number of patients available for screening
across four sites (1456) in one year, or 12 months.
Stage 2: adjust for mitigating factors
The Stage 2 metric is the percentage of participants esti-
mated to be eligible and willing to take part, or the con-
version rate. We adjusted for known mitigating factors
from the literature to calculate a potential conversion rate.
After a systematic review, we thought it reasonable to as-
sume that approximately 20% of patients with a total knee
replacement would experience long term pain [24–26].
We then accounted for those patients deciding not to take
part. Rather than set the conversion rate at 20%, we esti-
mated that 50% of these patients would not meet the eligi-
bility criteria and that 50% of those remaining would
decline to take part, which leads to a potential conversion
rate of 5%. The screening and randomisation logs can be
used to calculate actual conversion rates by dividing the
number of randomisations by the number screened. This
can be used to project recruitment by site as well as the
trial overall. Stage two in the equation below is 20% x 50%
x 50%, or a conversion rate of 5%.
Stage 3: further adjustments
The Stage 3 metric is an adustment for expected losses
to recruitment. Further adjustments were made to ac-
count for time periods during which all specialities ex-
perience challenges in recruitment to research studies.
For example, the end of year holiday period is known to
present challenges. We assumed that December and
January would each lose half the potential recruitment.
Stage three in the equation below represents 11 full re-
cruitment months out of 12 (11/12), or a loss of 1 month
recruitment per year.
Stage 4: project recruitment
The Stage 4 metric is the total recruitment period. Once
we had estimated our screening population and conver-
sion rate, we applied our projection equation. This gave
us an idea of what overall recruitment would be if all
sites started on day one and recruited for the full 30
months. Stage four in the equation below represents the
total recruitment period of 30 months.
Projection equation
Projected recruitment ¼ Stage 1 Stage 2 Stage 3
Number of time periods
This equation was used to calculate the projected
recruitment for our trial based on information from the
original four sites after the internal pilot:
Projected recruitment ¼ 1456
12 months
 0:2 0:5 0:5ð Þ  11
12
 
 30 months
¼ 166:8
This indicated that the current four sites in the pilot
would not be sufficient to attain a sample size of 380. The
information was then entered into a spreadsheet to project
recruitment and estimate how many additional sites
would be required to achieve the additional 214 randomi-
sations, based on the patient population. Projections for
each potential site were calculated to take into account
the impact on overall trial recruitment. Five new sites
were opened using a staged approach over time.
Trial delivery stage
Monthly screening log returns were used to calculate
actual conversion rates. These were also used to ob-
serve whether sites were able to screen the agreed
number of patients. When targets were not met, we
worked with the site team to investigate ways to in-
crease screening numbers. For example, we asked if
there were particular operating lists or surgeons that
were being missed or whether screening searches
were being focused on a particular geographic area.
Projections were then adjusted based on actual re-
cruitment and conversion rate data. Actual and esti-
mated data were included in the same projection by
using actual data on current sites and projected data
based on the trial average and a potential new site’s
screening population.
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These projections were used to estimate when the
sample size would be reached and how many randomi-
sations could be expected from recruiting sites, both
current and potential, and by month and overall. This
informed our decision-making on how many further
sites would be required. Figure 1 shows an example pro-
jection created from month 7 to estimate recruitment
compared to the target after opening four potential sites
in succession. The formulas used to create these projec-
tions can be found in Additional file 4.
Discussion
Feasibility assessments and recruitment projections
are useful tools in designing a trial. Combined with
an internal pilot and qualitative work, they allow trial
management teams to set realistic recruitment targets
and identify ways to improve recruitment, increasing
the likelihood that the sample size is met. Using these
tools during the pilot of a trial can optimise recruit-
ment into the main trial and ensure delivery on time.
Our internal pilot and the development of easy-to-use
site feasibility and projection tools have helped to im-
prove recruitment for the main trial, and key learning
points can be applied to other trials.
The feasibility assessment that we have described is
specific to the context of our trial; however, a similar
approach could be applied to other trials with appro-
priate modifications. The main points to consider as
Fig. 1 Example projection chart estimating recruitment with the addition of four potential sites opened in succession
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outlined by the NIHR good clinical practice training
are the patient population, trial staffing and training,
clinical support services, and equipment and facilities.
After the feasibility data have been collected and the
sites confirmed, the setup is important to consider
when setting projections of realistic targets.
Adjusting projections based on screening data is
contingent on the submission of accurate screening
logs. It has been argued that, despite the Consolidated
Standards of Reporting Trials (CONSORT) guidelines,
it is not worth collecting screening data [37], while
others report the necessity of collecting screening
data to comply with CONSORT guidelines and to
report on the generalisability of the trial results [38,
39]. When published, screening data are not only im-
portant for transparency, but are also helpful for esti-
mating the patient population in future trials.
Screening data collected within a trial are valuable in-
formation, which may be used to project future
recruitment.
Although projections are a useful tool for predicting
recruitment, unexpected events will occur. We would
suggest that these can be usefully viewed as a learn-
ing experience. Following the pilot, we learned to set
recruitment to zero for the first month at new sites
to give the team time to adjust to the trial procedures
as well as to allow for a lengthy screening process.
Adjustments for circumstances related to specific tri-
als are important, especially when accounting for con-
ditions that are affected by the time of year. Our
projection tool enables the clear identification of the
number of patients that could be randomised at each
site and whether further study sites may be required.
Our projection equation can be used to account for
different variables, depending on the needs of the
trial. To estimate the time required to recruit a sam-
ple, the equation is simply rearranged to divide the
sample size by the results of stages 1–3:
Numer of time periods ¼ Sample size
Stage 1 Stage 2 Stage 3
Although the methods described are specific to one
trial, the concepts can be applied to many trials, both
in the delivery phase and design phase. Information
obtained from an internal pilot, including qualitative
findings, can be used for site feasibility assessments
and to create recruitment projections. This informa-
tion may be used to improve recruitment procedures
and processes and can inform a decision on whether
to expand to additional trial sites. Use of these tools
may help trial teams increase the likelihood that the
sample size will be met.
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